News

Under the terms of the agreement, an immediate upfront payment of US$7.0 million is due to the co-investment partners and an additional fee of up to US$2.0 million

The new Agreement builds on the strategic collaboration between the two companies announced in January 2015 and will see C4XD and Evotec work together to develop new small

The new collaboration will explore the potential benefits of combining BMS’ anti-PD-1 antibody with Nektar’s CD122-biased agonist, NKTR-214, in five tumor types. The phase 1/2 clinical trials will

STELARA is the first biologic therapy for Crohn’s disease targeting interleukin (IL)-12 and IL-23 cytokines, which play a key role in inflammatory and immune responses. William J. Sandborn, MD,

In this trial, Epidiolex, when added to the patient’s current treatment, achieved the primary endpoint for both dose levels with high statistical significance. During the treatment period, patients

Sanofi Pasteur committed to researching and developing a vaccine to prevent Zika in February, shortly after the World Health Organization declared an emergency. In July 2016, Sanofi Pasteur

The acquisition is expected to close in the next three weeks.  Terms of the transaction were not disclosed. Established in 1995, ExecuPharm provides clients with qualified professionals across

The US drugmaker said its analysis determined that splitting Pfizer Innovative Health and Pfizer Essential Health would not improve cash flow or better position the businesses competitively. The

The parties hope to complete the deal in Q1 2017.  Pharmaron sees this as a unique opportunity to acquire state-of-the-art Good Manufacturing Practice (GMP) standard facilities for the